Lux Biosciences to Provide Update on Four Pipeline Programs, Including Two Phase 3 Clinical Programs, at ARVO
"We will be showcasing at ARVO the depth of Lux Biosciences' development pipeline, and we are very pleased to report remarkable progress with all of our projects," said Ulrich Grau, Ph.D., Lux Biosciences President and Chief Executive Officer. "Notably, during this meeting we have presentations on our two phase 3 clinical programs in uveitis and in cornea transplantation. We also will be presenting highly original work with bioerodible polymers as well as a clear, mixed micellar formulation for ocular delivery of our next generation calcineurin inhibitor (LX212 and LX214, respectively). These latter two product candidates are tailor-made for dry eye and other, highly prevalent chronic inflammatory diseases of the eye." -0-
Lux Biosciences' presentations include two orally presented papers:
Program Number: 1146
Abstract Title: Design of Phase 2/3 Clinical Trials of a
Cyclosporine A Eluting Implant, LX201,
for the Prevention and Treatment of
Corneal Allograft Rejection or Graft
Failure in Patients at High Risk
Session Number: 210
Session Date/Start Time: Monday Apr 28, 2008, 8:30 AM - 10:15 AM
Presentation Start-End Time: 8:30:00 AM - 8:45:00 AM
Room: Floridian Ballroom BCD
Program Number: 5007
Abstract Title: Development of a Bioerodible Insert for
the Ocular Delivery of a Novel Next
Generation Calcineurin Inhibitor
Session Number: 501
Session Date/Start Time: Thursday May 1, 2008, 8:30 AM - 10:15 AM
Presentation Start-End: 9:30:00 AM - 9:45:00 AM
Room: Room 114
Four poster presentations relating to LX 211, LX201 and LX214 will
also be included as part of the ARVO meeting program:
Program Number: 114
Abstract Title: Development and Characterization of a
Clear, Mixed Micellar Formulation of a
Next-Generation Calcineurin Inhibitor,
for Treatment of Dry Eye Syndrome
Session Number: 106
Session Date/Start Time: Sunday Apr 27, 2008, 8:30 AM - 10:15 AM
Poster Board: A141
Room: Hall B/C
Program Number: 1964
Abstract Title: Preclinical Acute Toxicity and
Pharmacokinetics of Episcleral LX201
Implants in Rabbits
Session Number: 257
Session Date/Start Time: Monday Apr 28, 2008, 11:15 AM - 1:00 PM
Poster Board: D935
Room: Hall B/C
Program Number: 3883
Abstract Title: Design of Phase 2/3 Clinical Trials of a
Novel Calcineurin Inhibitor, LX211, for
the Treatment of Non-Infectious Uveitis
Session Number: 418
Session Date/Start Time: Wednesday Apr 30, 2008, 8:30 AM - 10:15
AM
Poster Board: A503
Room: Hall B/C
Program Number: 4745
Abstract Title: LX211 (ISA247) Suppresses Anti-CD3
Activated Human T-Cell Proliferation and
Effectively Treats Experimental
Autoimmune Uveitis in Rats
Session Number: 479
Session Date/Start Time: Wednesday Apr 30, 2008, 3:00 PM - 4:45 PM
Poster Board: A551
Room: Hall B/C
About Lux Biosciences
Lux Biosciences, Inc. is a privately held biotechnology company focused on ophthalmic diseases. The company has a staged product portfolio of potentially first-in-class therapies distinguished by their short-term path to commercialization and potential to generate high revenue growth. The portfolio includes:
-- Two Phase III clinical-stage projects including: i) LX211, the oral formulation of a next-generation calcineurin inhibitor developed as steroid sparing therapy for the treatment of non-infectious uveitis, and ii) LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye for the prevention of rejection cornea transplant recipients. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007 and include sites in North America and Europe.
-- LX214, a novel topical eye drop formulation currently in IND-enabling studies with a target date for entry into the clinic in mid 2008. LX214 is based on Lux' proprietary next-generation calcineurin inhibitor and is targeted towards other chronic inflammatory diseases of the eye, most notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis.
-- Several earlier stage projects based on proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.
For more information on Lux Biosciences, please visit the company's website at http://www.luxbio.com.
Contact
Lux Biosciences, Inc.
Ulrich Grau, Ph.D., +1-201-946-0221
Ulrich.grau@luxbio.com
or
Kureczka/Martin Associates
Joan Kureczka, +1-415-821-2413 (Media)
Jkureczka@comcast.net
Posted: February 2008
